TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06361862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active alarms from WARD software
Description: Wireless continuous vital sign monitoring with real time staff alerts
Study: NCT04075786

Intervention type: OTHER
Intervention: Survey
Description: Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
Study: NCT05713695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full MISSION
Description: MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage Only Delivered by a Peer Specialist
Description: Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
Study: NCT05143164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrocolloid dressing
Description: Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate, Topical
Description: Application of gentamicin to exit site daily
Study: NCT05105048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05671497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 MG
Description: An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
Study: NCT05825222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-PR-01 (Low dose)
Description: One Capsule to be consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-PR-01 (High Dose)
Description: One Capsule to be consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Capsule to be consumed twice a day
Study: NCT06119152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESA
Description: Intervention group is monitored via remote bp monitoring and telehealth device.
Study: NCT05735665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bowel ultrasound
Description: Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: colonoscopy
Description: Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
Study: NCT05776290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
Study: NCT05442450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral semaglutide
Description: Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
Study: NCT05390177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video type
Description: One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video type
Description: One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
Study: NCT05956067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Light stimulation
Description: A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equal Energy White stimulation
Description: A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-cone modulating white light
Description: A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
Study: NCT05864404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam-remifentanil
Description: In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine-remifentanil
Description: In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
Study: NCT05413941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
Study: NCT06492772

Intervention type: OTHER
Group type: OTHER
Intervention: experimental group
Description: The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
Study: NCT06120868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surefil one®
Description: For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek One
Description: Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
Study: NCT06051071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
Study: NCT06543563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: After the craniotomy, a continuous infusion of normal saline at a rate of 0.3 ml/kg/h is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
Study: NCT05133583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people.
Study: NCT05325372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary block
Description: it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infraclavicular block
Description: it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
Study: NCT04684108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG301
Description: Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Study: NCT05994976

Intervention type: PROCEDURE
Intervention: Stool samples collection
Description: biomarkers analysis

Intervention type: PROCEDURE
Intervention: Stool samples collection
Description: biomarkers analysis

Intervention type: PROCEDURE
Intervention: Stool samples collection
Description: biomarkers analysis
Study: NCT06133634

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Fisetin dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to fisetin capsules
Study: NCT05879237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori triple therapy
Description: Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori triple therapy
Description: Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month
Study: NCT05421468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-Thyroxine time B (5-15 minutes Before dawn)
Description: Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-Thyroxine time B (5-15 minutes Before dawn)
Description: Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Study: NCT05638347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7085 tablets
Description: Single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7085 tablets
Description: Single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Single oral administration
Study: NCT05396937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multifocal Stereotactic Radiotherapy
Description: Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
Study: NCT05331469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH basal insulin titration
Description: Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH basal insulin titration
Description: Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
Study: NCT06423651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (REHACOP)
Description: REHACOP is a structured neuropsychological rehabilitation program that covers most of the cognitive deficits present in psychotic disorder: attention, learning and memory, executive functions, language, social cognition, daily life activities, social skills and psychoeducation. The modules of language, social cognition and psychoeducation will not be used in the present clinical trial. Each module includes a hierarchy of exercises based on the cognitive subarea to be worked on and the grade of difficulty demanded for the performance of each task.The format of the sessions will be the same as MCT, that is, groups of 6-10 patients who will receive weekly sessions of 45-60 minutes in length. In this case, the duration of the intervention will be 12 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training (MCT)
Description: The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Description: The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.
Study: NCT04714398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-In Recruitment
Description: Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-Out Recruitment
Description: Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
Study: NCT05997342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3912 tablets
Description: TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.
Study: NCT05631743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-CBT
Description: The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: The previously developed commercial VR program involves guided relaxation and meditation techniques.
Study: NCT05038540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Phase 1 periodontal therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Phase 1 periodontal therapy
Study: NCT05893992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids (omnidirectional)
Description: Device for hearing loss compensation with microphone sensitivity all around the listener.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids (directional)
Description: Device for hearing loss compensation with microphone sensitivity in front of the listener.
Study: NCT06321185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal TAP block
Description: Subcostal TAP block will be applied after intubation and before surgery. A local anesthetic solution of 20 ml 0.25% bupivacaine for each side will be injected bilaterally between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Port site local anesthetic infiltration
Description: After intubation and before port placements, a solution of 20 ml 0.25% bupivacaine will be infiltrated into the laparoscopic port sites. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention or local anesthetic administration
Description: There will not be an intervention or local anesthetic administration. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher.
Study: NCT05893992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided
Description: Control condition